Patents by Inventor Pablo E. Vivas-Mejia

Pablo E. Vivas-Mejia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
    Patent number: 11090266
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: August 17, 2021
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Nanoliposomal c-MYC-siRNA Inhibits In Vivo Tumor Growth of Cisplatin-Resistant Ovarian Cancer
    Publication number: 20200179284
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Application
    Filed: February 3, 2020
    Publication date: June 11, 2020
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
    Patent number: 10548842
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: February 4, 2020
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • NANOLIPOSOMAL FORMULATION FOR TARGETING INTEGRIN-LINKED KINASE (ILK) WITH SMALL-INTERFERENCE RNA AND A METHOD FOR TREATING OVARIAN CANCER
    Publication number: 20180193267
    Abstract: The invention provides a nanoliposomal formulation that targets Integrin Linked Kinase (ILK) with small-interfering RNA (siRNA) in cisplatin-resistant ovarian cancer. A reduction in cell proliferation and invasion was observed upon ILK depletion by siRNA treatment. Furthermore, an ILK-targeted siRNA-liposomal formulation reduced tumor metastasis in an ovarian cancer mouse model. SiRNA-mediated ILK silencing reduced the phosphorylation levels of AKT and GSK3?. The nanoliposomal formulation is formed by lipids and ILK-siRNA according to specific ratios.
    Type: Application
    Filed: December 19, 2016
    Publication date: July 12, 2018
    Inventor: Pablo E. Vivas-Mejia
  • Nanoliposomal c-MYC-siRNA Inhibits In Vivo Tumor Growth of Cisplatin-Resistant Ovarian Cancer
    Publication number: 20180185284
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 5, 2018
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
    Patent number: 9895312
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: February 20, 2018
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Nanoliposomal c-MYC-siRNA Inhibits In Vivo Tumor Growth of Cisplatin-Resistant Ovarian Cancer
    Publication number: 20150306036
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Application
    Filed: April 8, 2015
    Publication date: October 29, 2015
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez